Clarivate Analytics, a global insights and analytics company, announced the launch of its annual “Cortellis Drugs to Watch” report using data and analytics from Cortellis, the company’s suite of life science intelligence solutions. The report highlights seven new drugs forecasted to sell at blockbuster status ($1billion or higher) by 2023.
The drugs include Upadacitinib (AbbVie – US), which treats rheumatoid arthritis; Zolgensma (AveXis – US), which treats spinal muscular atrophy; Roxadustat (AstraZeneca – UK, FibroGen – US, Astellas – Japan), which treats anemia in chronic kidney disease patients on dialysis; Ultomiris (Alexion – US), which treats paroxysmal nocturnal hemoglobinuria; Skyrizi (Boehringer Ingelheim – DE, AbbVie – US), which treats psoriasis; AR-101 (Aimmune Therapeutics – US), which treats peanut allergies; and LentiGlobin (bluebird bio – US), which treats beta-thalassemia in transfusion-dependent patients.
For more information about each drug, how much is forecasted in sales for 2023, and to download the full report, visit here.
FDA Approves Pfizer’s Beqvez for the Treatment of Adults with Moderate to Severe Hemophilia B
April 26th 2024Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.